- Home
- RNAC
as 04-18-2025 1:42pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 273.8M | IPO Year: | 2016 |
| Target Price: | $40.83 | AVG Volume (30 days): | 127.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.85 - $41.87 | Next Earning Date: | 05-07-2025 |
| Revenue: | $38,913,000 | Revenue Growth: | 49.64% |
| Revenue Growth (this year): | -91.26% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Apr 9 '25 | Buy | $10.30 | 149,075 | $1,522,517.04 | 656,513 | |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Mar 18 '25 | Buy | $14.99 | 89,863 | $1,371,154.37 | 656,513 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewswire
17 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
18 days ago
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
a month ago
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 03/21/2025
TipRanks
a month ago
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
Simply Wall St.
a month ago
Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
a month ago
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.